stockrowSarepta Therapeutics, Inc.
SRPT Healthcare Biotechnology
Sarepta Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.2 billion, up 15.6% from fiscal 2024.
- Revenue
- −4.51%
- EPS
- +46.0%
- Free cash flow
- +231.8%
- Total debt
- −17.2%
Quarter to September 2026, against a year earlier
Follow SRPT
Alert me
Sarepta Therapeutics, Inc. (SRPT) EBITDA
Sarepta Therapeutics, Inc.'s EBITDA for fiscal 2025 was −$660.6M, compared with $215.5M in fiscal 2024. Over the twelve months to 30 June 2026 it was −$101.5M. Over the past ten years it has ranged from −$681.1M (fiscal 2019) to $215.5M (fiscal 2024); the current reading is higher than 18% of that period. Sarepta Therapeutics, Inc. ranks 424th of 594 Biotechnology companies by EBITDA.
EBITDA, annual
Embed this chart
Annual newest first
| Period | EBITDA | Change |
|---|---|---|
| FY2025 | −$660.6M | — |
| FY2024 | $215.5M | — |
| FY2023 | −$269.6M | — |
| FY2022 | −$505.0M | — |
| FY2021 | −$421.8M | — |
| FY2020 | −$537.3M | — |
| FY2019 | −$681.1M | — |
| FY2018 | −$339.1M | — |
| FY2017 | −$164.4M | — |
| FY2016 | −$261.0M | — |
Quarterly newest first
| Period | EBITDA | Change |
|---|---|---|
| Jun 2026 | $22.8M | (93.81%) |
| Mar 2026 | $368.5M | — |
| Dec 2025 | −$406.7M | — |
| Sep 2025 | −$86.1M | — |
| 42 more quarters | Free account |
Against its own ten years
EBITDA against peers
| Company | EBITDA |
|---|---|
| HRMY Harmony Biosciences Holdings, Inc. compare | $243.7M |
| MESO Mesoblast Limited compare | −$57.9M |
| MRVI Maravai LifeSciences Holdings, Inc. compare | −$58.9M |
| TRVI Trevi Therapeutics, Inc. compare | −$59.4M |
| SRPT Sarepta Therapeutics, Inc. | −$101.5M |
| MAZE Maze Therapeutics, Inc. compare | −$143.2M |
| TRAX First Tracks Biotherapeutics, Inc. compare | −$164.7M |
| VIR Vir Biotechnology, Inc. compare | −$198.6M |
| REPL Replimune Group, Inc. compare | −$266.7M |
What EBITDA is
EBITDA shows what a company earns from its operations before interest, taxes and the non-cash charges for depreciation and amortization.
Reported line item